Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02824913 · ClinicalTrials.gov registry record · Phase 2
Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease
A Phase 2 study, sponsored by Parion Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02824913: Clinical Trial Phase 2 study, sponsored by Parion Sciences.
NCT02824913 is a Phase 2 study that was terminated before completion, run by Parion Sciences. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02824913, a Phase 2 study, was terminated before completion, sponsored by Parion Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this Phase 2a study is to assess changes in tear volume by the non-invasive techniques Ultra High Resolution Optical Coherence Tomography (UHR-OCT) following the administration of P-321 Ophthalmic Solution or Placebo in subjects with tear deficient dry eye disease.
Primary Outcome
Tear meniscus volume, from measurements of tear meniscus area by UHR-OCT and the length of the eyelid was estimated over time (0 to 6 hours) following administration of placebo or P-321 Ophthalmic Solution.
Interventions
- DRUG P-321 Ophthalmic Solution
- DRUG P-321 Ophthalmic Solution placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-07 |
| Est. Completion | 2017-03 |
| Phase | Phase 2 |
Why NCT02824913 stopped before completion
NCT02824913 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which P-321 Ophthalmic Solution is the first listed.
NCT02824913 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02824913 about?
NCT02824913 is a clinical study titled "Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease". The purpose of this Phase 2a study is to assess changes in tear volume by the non-invasive techniques Ultra High Resolution Optical Coherence Tomography (UHR-OCT) following the administration of P-321 Ophthalmic Solution or Placebo in subjects with tear deficient dry eye disease.
What is the current status of trial NCT02824913?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2016-07. Estimated completion is 2017-03.
What interventions are being tested in trial NCT02824913?
The interventions under investigation include: P-321 Ophthalmic Solution (DRUG), P-321 Ophthalmic Solution placebo (DRUG).
Who is sponsoring clinical trial NCT02824913?
This trial is sponsored by Parion Sciences, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02824913's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia